While IDH mutations have been established as one of the most important diagnostic and prognostic factors for adult diffuse gliomas, there remains significant intra-group heterogeneity in biologic behavior and clinical outcome in adult gliomas with significant survival outliers in all subtypes. The gene discussed is IDH1; the disease is central nervous system cancer.